Effect size measures in genetic association studies and age-conditional risk prediction

Human Heredity

Volumn 70, Issue 3, 2010, Pages 205-218

  So, Hon Cheong ^a   Sham, Pak C ^a,b,c,d  

^a Department of Psychiatry ^*  (United States)

^b Genome Research Centre   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Association study; Competing risks; Genetic counseling; Genetic risk prediction; Hazard ratio; Odds ratio; Relative risk

Indexed keywords

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BREAST CANCER; CANCER RISK; EFFECT SIZE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; HONG KONG; HUMAN; INCIDENCE; MORTALITY; RISK ASSESSMENT; RISK FACTOR;

AGE FACTORS; ALGORITHMS; ALZHEIMER DISEASE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC COUNSELING; GENETIC TESTING; HONG KONG; HUMANS; INCIDENCE; ODDS RATIO; RISK ASSESSMENT;

EID: 77956467624     PISSN: 00015652     EISSN: 14230062     Source Type: Journal    
DOI: 10.1159/000319192     Document Type: Article

References (32)

1. Hindorff L, Junkins H, Hall P, Mehta J, Manolio T: A catalog of published genome-wide association studies. Available at: http:// www.Genome.Gov/ gwastudies/ (accessed July 9, 2010).
2. Manolio TA, Brooks LD, Collins FS: A hap-map harvest of insights into the genetics of common disease. J Clin Invest 2008; 118: 1590-1605.
3. Zhang J, Yu KF: What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280:1690-1691.
4. Pearce N: What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993; 22:1189-1192.
5. Knol MJ, Vandenbroucke JP, Scott P, Egger M: What do case-control studies estimate? Survey of methods and assumptions in published case-control research. Am J Epidemiol 2008; 168:1073-1081.
6. Rothman KJ, Greenland S, Lash TL: Modern Epidemiology, ed 3. Philadelphia, Lippincott Williams & Wilkins, 2008.
7. Preston SH, Heuveline P, Guillot M: Demography : Measuring and Modeling Population Processes. Oxford, UK and Malden, MA, Blackwell Publishers, 2001.
8. Keiding N: Age-specific incidence and prevalence - a statistical perspective. J Roy Stat Soc Ser A Stat Soc 1991; 154:371-412.
9. Miettinen O: Estimability and estimation in case-referent studies. Am J Epidemiol 1976; 103:226-235.
10. Freeman J, Hutchison GB: Prevalence, incidence and duration. Am J Epidemiol 1980; 112: 707-723.
11. Pearce N: Effect measures in prevalence studies. Environ Health Perspect 2004; 112: 1047-1050.
12. Alho JM: On prevalence, incidence, and duration in general stable-populations. Biometrics 1992; 48: 587-592.
13. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-1886.
14. Dupont WD: Converting relative risks to absolute risks: a graphical approach. Stat Med 1989; 8:641-651.
15. Dupont WD, Plummer WD Jr: Understanding the relationship between relative and absolute risk. Cancer 1996; 77:2193-2199.
16. Merrill RM, Feuer EJ: Risk-adjusted cancer-incidence rates (United States). Cancer Causes Control 1996; 7:544-552.
17. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T: The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993; 85:892-897.
18. Fay MP: Estimating age conditional probability of developing disease from surveillance data. Popul Health Metr 2004; 2:6.
19. Fay MP, Pfeiffer R, Cronin KA, Le C, Feuer EJ: Age-conditional probabilities of developing cancer. Stat Med 2003; 22:1837-1848.
20. Neuhaus J: Bias due to ignoring the sample designincase -control studies . Aust NZ J St at 2002; 44: 285-293.
21. Prentice RL, Pyke R: Logistic disease incidence models and case-control studies. Biometrika 1979; 66: 403-411.
22. Symons MJ, Moore DT: Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol 2002; 55:893-899.
23. Podgor MJ, Leske MC: Estimating incidence from age-specific prevalence for irreversible diseases with differentia l mortality. Stat Med 1986; 5:573-578.
24. Preston S, Wang H: Intrinsic growth rates and net reproduction rates in the presence of migration. Popul Dev Rev 2007; 33:657-666.
25. Hakama M, Hakulinen T: Estimating the expectation of life in cancer survival studies with incomplete follow-up information. J Chronic Dis 1977; 30: 585-597.
26. Chiu HF, Lam LC, Chi I, Leung T, Li SW, Law WT, Chung DW, Fung HH, Kan PS, Lum CM, Ng J, Lau J: Prevalence of dementia in Chinese elderly in Hong Kong. Neurology 1998; 50:1002-1009. (Pubitemid 28212829)
27. Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST: Alzheimer disease and mortality: A 15-year epidemiological study. Arch Neurol 2005; 62: 779-784.
28. Farrer L, Cupples L, Haines J, Hyman B, Ku-kull W, Mayeux R, Myers R, Pericak-Vance M, Risch N, Van Duijn C: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 13 4 9 -135 6 .
29. Li X, Sundquist J, Sundquist K: Age-specific familial risks of depression: A nation-wide epidemiological study from Sweden. J Psy-chiatr Res 20 08; 42: 808-814. (Pubitemid 351787736)
30. Yang Q, Flanders WD, Moonesinghe R, Io-annidis JP, Guessous I, Khoury MJ: Using lifetime risk estimates in personal genomic profiles: Estimation of uncertainty. Am J Hum Genet 2009; 85:786-800.
31. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999; 91:1541-1548.
32. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91:1829-1846.